In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Published Sep 22, 2020

In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Already approved for EGFR-positive metastatic non-small cell lung cancer, osimertinib (Tagrisso ) brings major benefits in early cancer, too.

NOW
PLAYING
Nearly One Year After Beating Prostate Cancer, 'TODAY's' Al Roker Is Living Life To The Fullest While Hosting The Tokyo Olympics
NOW
PLAYING
Lung Cancer Patients Who Quit Smoking Live Longer
NOW
PLAYING
59-year-old Sailor and Lung Cancer Survivor Santiago Lange is Headed for His Seventh Olympic Games
NOW
PLAYING
Pfizer Suspends Distribution of Anti-Smoking Drug Chantix Over Possible Cancer Risk
NOW
PLAYING
87% of Eligible Patients Skip Lung Cancer Screening, Analysis Finds
NOW
PLAYING
Fox Anchor Lindy Thackston Shares Her 'Scanxiety'
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.